J&J Receives $117M Grant From E.U.-Supported Innovative Medicines Initiative For Ebola Vaccine Efforts

Associated Press: Johnson & Johnson Ebola groups get $117M in funding
“Johnson & Johnson is working with a slew of organizations to speed up development of an Ebola vaccine, and the company said Friday that a European health organization awarded them $117 million…” (1/16).

Financial Times: J&J receives €100m E.U. injection for Ebola vaccine development
“J&J and its partners are the main beneficiaries of a €215m funding package from the E.U.-backed Innovative Medicines Initiative announced on Friday to support development and manufacturing of vaccines and diagnostic tools for Ebola…” (Ward, 1/16).

Wall Street Journal: J&J Gets Grant to Speed Up Ebola Vaccine
“…The grants will go toward clinical trials and production of J&J’s experimental vaccine and a campaign to raise awareness of the vaccination. In October, J&J committed $200 million to developing the treatment and has since been looking for funding partners…” (Dulaney, 1/16).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.